National Cancer Institute; Notice of Meeting, 52452-52453 [2016-18686]
Download as PDF
52452
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
2019, Bethesda, MD 20892, 301–443–2861,
marmillotp@mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Neuroscience Review
Subcommittee.
Date: October 27, 2016.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Alcohol Abuse
and Alcoholism, National Institutes of
Health, Terrace Level Conference Room 508–
509, 5635 Fishers Lane, Rockville, MD 20852.
Contact Person: Beata Buzas, Ph.D.,
Scientific Review Officer, National Institute
On Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
2081, Rockville, MD 20852, 301–443–0800,
bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–18688 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and co-
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
development research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Synthetic HumanDerived Peptides and Peptidomimetics
for Cancer Therapeutics
Keywords: Rpn13, selective
proteasome inhibitor, proteasome
ubiquitin receptors, (competition:
carfilzomib and bortezomib too toxic,
resistance developed), solid tumors,
hematological cancer, HPV associated
cancer, ovarian cancer, prostate cancer,
gastric cancer, breast cancer, or
colorectal cancer
Description of Technology: FDA
approved 26S proteasome inhibitors,
such as carfilzomib and bortezomib
(Velcade®) have proven to be effective at
treating hematologic cancers. However,
resistance to these agents as well as
their toxicity have raised concerns and
highlight the need for new 26S
proteasome inhibitors.
Investigators at the NCI’s Structural
Biophysics Laboratory have developed a
new class of proteasome inhibitors.
They are hRpn2-derived peptides
capable of specifically targeting the Pru
domain of hRpn13. Disruption of the
Rpn2/Rpn13 interaction inhibits
proteolysis by a mechanism that differs
from those of the approved proteasome
inhibitors.
Potential Commercial Applications:
• New class of proteasome inhibitors,
targeting hRpn13 of the regulatory
particle.
Value Proposition:
• Synergistic with, and more specific
than, known proteasome inhibitors.
• Alternate mechanism of action
compared to approved proteasome
inhibitors.
Development Stage: Discovery (Lead
ID).
Inventor(s): Kylie J. Walters (NCI), Fen
Liu (NCI), and Xiuxiu Lu (NCI).
Intellectual Property:
HHS Reference No. E–278–2015/0–
US–01.
US Provisional Application 62/
222,530 (HHS Reference No. E–278–
2015) filed September 23, 2015 entitled
‘‘Human RPN2 Derived Peptides Useful
For Treating Cancer’’.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Publications: 1. Lu X., et al., 2015
PLoS One 2015 Oct 14;10(10) PMID:
26466095.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–18689 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is
hereby given of the meeting of the
National Cancer Advisory Board
(NCAB).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: September 7, 2016, 9:00 a.m. to
05:00 p.m.
Agenda: Programs reports and
presentations; business of the Board.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Closed: September 7, 2016, 04:00 p.m. to
05:00 p.m.
E:\FR\FM\08AUN1.SGM
08AUN1
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
Agenda: Review of NCAB grant
applications.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page, NCAB: https://
deainfo.nci.nih.gov/advisory/ncab/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Consequences of Aging.
Date: August 15, 2016.
Time: 3:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Pat Manos, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5200,
MSC 7846, Bethesda, MD 20892, 301–408–
9866, manospa@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 2, 2016.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–18687 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Modification of the National Customs
Automation Program (NCAP) Test
Concerning the Automated
Commercial Environment (ACE) Portal
Accounts To Establish the Protest Filer
Account and Clarification That the
Terms and Conditions for Account
Access Apply to All ACE Portal
Accounts
National Institutes of Health
AGENCY:
[FR Doc. 2016–18686 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
mstockstill on DSK3G9T082PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
This document announces
U.S. Customs and Border Protection’s
(CBP’s) plan to modify the National
Customs Automation Program (NCAP)
test concerning Automated Commercial
Environment (ACE) Portal Accounts to
establish the ACE Protest Filer Account.
After CBP deploys the ACE Protest
Module test at a later date, participants
with an ACE Protest Filer Account will
be able to file an electronic protest in
ACE. This document also clarifies that
CBP’s previously published terms and
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
52453
conditions governing access to and use
of the NCAP test of ACE Portal
Accounts apply to all ACE Portal
Accounts, including all ACE Portal
Account types created after the
previously published terms and
conditions. All other aspects of the ACE
Portal Accounts Test remain the same as
set forth in previously published
Federal Register notices.
DATES: The modifications and
clarifications of the ACE Portal Account
Test made by this notice are effective on
August 8, 2016.
The clarification to the terms and
conditions applies to all ACE Portal
Accounts regardless of when the
account was created.
ADDRESSES: Comments concerning this
notice and any aspect of the modified
ACE Portal Account Test may be
submitted at any time during the testing
period via email to Josephine
Baiamonte, ACE Business Office (ABO),
Office of Trade at josephine.baiamonte@
cbp.dhs.gov. In the subject line of your
email, please indicate, ‘‘Comment on
ACE Portal Account Test FRN’’.
FOR FURTHER INFORMATION CONTACT: For
technical questions related to the
application or requests for an ACE
Portal Account, including ACE Protest
Filer Accounts, contact the ACE
Account Service Desk by calling 1–866–
530–4172, selecting option 1, then
option 2, or by emailing ACE.Support@
cbp.dhs.gov for assistance.
SUPPLEMENTARY INFORMATION:
I. Automated Commercial Environment
(ACE)
A. The National Customs Automation
Program
The National Customs Automation
Program (NCAP) was established by
Subtitle B of Title VI—Customs
Modernization in the North American
Free Trade Agreement (NAFTA)
Implementation Act (Customs
Modernization Act) (Pub. L. 103–182,
107 Stat. 2057, 2170, December 8, 1993)
(19 U.S.C. 1411). Through NCAP, the
thrust of customs modernization was on
trade compliance and the development
of ACE, the planned successor to the
Automated Commercial System (ACS).
ACE is an automated and electronic
system for commercial trade processing
which is intended to streamline
business processes, facilitate growth in
trade, ensure cargo security, and foster
participation in global commerce, while
ensuring compliance with U.S. laws and
regulations and reducing costs for CBP
and all of its communities of interest.
The ability to meet these objectives
depends on successfully modernizing
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Pages 52452-52453]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18686]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is hereby given of the meeting of the
National Cancer Advisory Board (NCAB).
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting. The open session will be
videocast and can be accessed from the NIH Videocasting and Podcasting
Web site (https://videocast.nih.gov).
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Open: September 7, 2016, 9:00 a.m. to 05:00 p.m.
Agenda: Programs reports and presentations; business of the
Board.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Closed: September 7, 2016, 04:00 p.m. to 05:00 p.m.
[[Page 52453]]
Agenda: Review of NCAB grant applications.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, Room
7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page, NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm, where
an agenda and any additional information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-18686 Filed 8-5-16; 8:45 am]
BILLING CODE 4140-01-P